M&A activity will remain moderately strong in both sectors.
2019 deal value grew significantly in both sectors. Life sciences deal value remains at a level several times that of chemicals. Despite a record year for life sciences, M&A activity has been slightly lower in H2 2019. The focus on high-growth segments and therapeutical areas like oncology and on core businesses with innovative drugs have been the key deal drivers in life sciences in 2019.
The chemical sector suffered a decline in M&A deal volume, partly driven by an economic downturn in 2019. Excluding the SABIC deal (USD 69.1 billion), the same holds true for total deal value. Large deals have been mostly related to portfolio optimization.
Browse directly through the publication
© 2020 KPMG AG Wirtschaftsprüfungsgesellschaft, ein Mitglied des KPMG-Netzwerks unabhängiger Mitgliedsfirmen, die KPMG International Cooperative (“KPMG International”), einer juristischen Person schweizerischen Rechts, angeschlossen sind. Alle Rechte vorbehalten.